MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS)

View Full Size 

Download

• Full Size JPEG, 608x661, 152.0 KB
• Small JPEG, 442x480, 122.8 KB
• Preview JPEG, 132x144, 41.3 KB
• Thumbnail JPEG, 64x70, 28.5 KB